Moderna, Inc. (MRNA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 63.16 |
| Open | 62.53 |
| Bid | 61.00 x 800 |
| Ask | 61.16 x 800 |
| Day's range | 61.03 - 62.90 |
| 52-week range | 61.03 - 170.47 |
| Volume | |
| Avg. volume | 4,620,431 |
| Market cap | 23.475B |
| Beta (5Y monthly) | 1.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -15.35 |
| Earnings date | 31 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 101.94 |
PR NewswireInvaio Sciences Appoints André Andonian as Chairman of the Board of Directors
Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio.
Investor's Business DailyIs Moderna Stock A Sell After The Company Slashed Its R&D Budget?
Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell?
ZacksARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
© 2024 Yahoo. All rights reserved.